The association of chronic inflammatory demyelinating polyneuropathy (CIDP) and carcinoma has rarely been reported and its relevance is debated. Thirty three consecutive patients with probable or definite CIDP (idiopathic or associated with M protein) were investigated. Three patients with definite CIDP had a concomitant carcinoma. One had an IgM paraprotein. Steroids and intravenous immunoglobulins were effective. (7 Neurol Neurosurg Psychiatry 1996;60:188-190) Keywords: chronic inflammatory demyelinating polyneuropathy; cancer; paraneoplastic neurological syndrome; monoclonal gammopathy axilla, and Erb's point and in the peroneal and tibial nerves at the ankle and knee as described by Kimura." F waves were elicited 10 times for each test by supramaximal stimulation and measured by the minimal latency. The criteria for partial conduction blocks were a > 20% drop in the p amplitude between proximal and distal sites with a < 15% change in duration. Sensory conduction velocities were examined in the median, ulnar, and sural nerves. The limits of normal values were obtained from the laboratory. Electromyography was performed with a concentric needle electrode in the tibialis anterior, extensor digitorum brevis, abductor digiti minimi, and abductor pollicis.
A wide range of peripheral neuropathies have been reported as remote effects of cancer. ' 2 At present, only subacute sensory or motor neuronopathies are well established paraneoplastic syndromes.' Sensorimotor neuropathies associated with cancer are a heterogeneous group.
I
Among them, primary demyelinating neuropathies have rarely been reported. We describe carcinoma in three patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
Materials and methods
We investigated 33 consecutive patients with probable or definite CIDP using the criteria of the ad hoc Subcommittee of the American Academy of Neurology.' Eighteen had idiopathic CIDP, one systemic lupus erythematosus, 11 IgG or IgM monoclonal gammopathy, and three a carcinoma.
Laboratory studies included chest radiography, biological tests as recommended by the ad hoc committee,5 and search for anti-GM1 antibodies. The serum samples of the three patients with a carcinoma were tested by immunofluorescence on rat brain and human nerve with anti-IgG and anti-IgM antisera. Unless specified, results of these studies were negative.
Motor conduction velocities were studied with a surface electrode in the median and ulnar nerves by stimulation at the wrist, elbow, Case reports PATIENT 1 In January 1992, a 73 year old man complained of progressive paraesthesia and numbness, sometime painful, in all four limbs. His gait became unsteady and his hands clumsy. He was referred after a two month progression. There were proximal and distal deficits in the lower limbs and in the hands corresponding to MRC grade 4 tConduction block between elbow and wrist or knee and ankle. ttProximal conduction block.
cent of teased fibres were demyelinated and 2% underwent axonal degeneration. Nerve biopsy was not performed in patient 1.
Discussion
The peripheral neuropathy of these three patients shared many features with CIDP. All of the patients showed a sensorimotor neuropathy affecting the four limbs with diffuse areflexia, progressing for at least two months. Their CSF contained high concentrations of protein and the studies of motor conduction velocities showed a demyelinating pattern. All of these are major criteria for the diagnosis of CIDP.5 When tested in two patients, intravenous IgGs and steroids were effective therapeutic agents. Although non-specific, response to these treatment are another characteristic of CIDP.9 Nerve biopsies showed mononuclear cell infiltrates and a mixture of demyelination, remyelination, and axonal degeneration. Similar lesions can be found in the nerves of patients with CIDP.9 10 Finally, the presence of anti-GM1 antibodies in one of our patients conforms to the finding that these antibodies can be detected in patients with CIDP."I It is interesting that CIDP preceded the discovery of adenocarcinoma by a few months. 15 In all these patients, the neuropathy usually occurred in a close temporal relation with the cancer and some patients, as our patients 2 and 3, improved after treatment of the tumour.'4 6 However, a spontaneous remission of CIDP cannot be ruled out.
As cancer is common, it is difficult to determine whether the association of carcinoma and CIDP is a coincidence or depends on a paraneoplastic process. In our series, three out of 33 patients referred for the diagnosis of dysimmune demyelinating neuropathy had a carcinoma. As few patients were studied, bias is possible. Some studies suggest that carcinomas can express antigens shared with Schwann cells '7 18 and that patients with tumours can produce antibodies reacting with these cells.'9 Interestingly, immunotherapy with melanoma cell preparations has been reported to induce demyelinating neuropathy. 20 Thus it is not unlikely that a neuropathy similar to CIDP can result from an autoimmune process induced by tumours.
